[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"superficial-basal-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:superficial-basal-cell-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100622473","high-intensity-focused-ultrasound-vs-cryotherapy-in-the-treatment-of-basal-cell-carcinomas-and-bowens-disease-in-adults-100622473",false,"NCT07384078","High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults","HIFU vs. CRYO - High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease - a Randomized Controlled Trial","HIFUvsCRYO","Inclusion Criteria:\n\n* age 18 years or older at the time of informed consent\n* ability to give informed consent and comply with the treatment protocol and follow-up plan\n* study lesion located between neck and knees\n* one of following histologically confirmed diagnosis: Superficial BCC with maximum diameter of 2.0 cm \u002F Nodular BCC with max. diameter of 1.5 cm \u002F BD with max. diameter of 2.0 cm\n\nExclusion Criteria:\n\n* Study lesion location in face, head, genitals, hands, or below the knee\n* Clinical\u002Fdermoscopical\u002Fhistological feature for high-risk\u002Faggressive BCC\n* Clinical\u002Fhistological sign for hypertrophic BD\n* Clinical\u002Fdermoscopical\u002Fhistological feature for Squamous cell carcinoma\n* Gorlin Golz syndrome\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":20,"type":21},294,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, randomized, controlled, and single-blinded non-inferiority clinical trial compare the efficacy and tolerability of high intensity focused ultrasound (HIFU) to standard cryotherapy in the treatment of low-risk basal cell carcinomas (BCCs) and Bowen's disease (BD) in adults. The main questions it aims to answer are:\n\n* Is HIFU an efficient treatment option for BCCs and BD?\n* What medical problems do participants get after HIFU?\n\nResearchers will compare HIFU to standard cryotherapy with liquid nitrogen to see if the ultrasound works to treat these local and low-risk non-melanosytic skin cancers.\n\nParticipants will:\n\n* Be treated either with HIFU (intervention) or cryotherapy (control).\n* Visit the clinic 4 weeks, 1-, 3- and 5 years after the treatment for check-ups, tests and survey questions.",[27,28,29,30,31],"Superficial Basal Cell Carcinoma","Nodular Basal Cell Carcinoma","Bowen's Disease","BCC","BD",[33,34,35,36,37,38,39,40,41],"HIFU","cryo","cryotherapy","high intensity focused ultrasound","basal cell carcinoma","Bowen's disease","superficial basal cell carcinoma","nodular basal cell carcinoma","non-surgical treatment","NOT_YET_RECRUITING","2026-01-26",{"date":45,"type":46},"2026-02-03","ACTUAL",{"date":48,"type":21},"2026-04-01",{"date":50,"type":21},"2032-12-31",{"name":52,"class":53},"Jussi Salonen","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":54},"100468577","phase-2-5-fluorouracil-and-calcipotriene-for-treatment-of-low-grade-skin-cancer-100468577","NCT05381597","5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer","Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ","Inclusion Criteria:\n\n* English-speaking\n* Having a previously untreated, biopsy-proven Superficial Basal Cell Carcinoma (sBCC) or Squamous Cell Carcinoma in Situ (SCCis) of the skin \\\u003C2 cm on the scalp, trunk, neck, or extremities, excluding hands, feet, and genitalia\n* Having a previously untreated, biopsy-proven sBCC or SCCis on the face, hands, feet, and genitalia who decline surgery or are otherwise not surgical candidates\n* Willing to undergo all protocol requirements and attend study-specific follow up clinic visits in addition to routine follow up visits\n* Participants may have multiple lesions enrolled in the study so long as the individual lesions are greater than 2 cm from each other\n* If a woman is of childbearing potential, the participant must be willing to take a pregnancy test before starting treatment and be on some form of birth control while receiving treatment. Birth control can include abstinence, oral contraceptive pill, intrauterine device, implanted birth control device, birth control patch, or the vaginal ring. The patient does not need to be on any form of birth control after they end therapy.\n\nExclusion Criteria:\n\n* Current or prior field treatment within 2 cm of the target BCC or SCCis\n* Periorbital lesions\n* Lesions that have been previously treated\n* Known allergy to any of the study medication ingredients\n* History of solid organ transplant or current immunosuppression\n* Genetic disorders associated with high skin cancer risk\n* Arsenic exposure\n* Cutaneous T-cell lymphoma\n* Current or prior radiation therapy at the site of the sBCC or SCCis\n* Women who are pregnant or currently breastfeeding\n* Prior psoralen plus Ultraviolet light (UVA) treatment at the site\n* Very high mortality risk at the start of the study\n* Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency\n* Demonstrated hypercalcemia or evidence of vitamin D toxicity\n* Lesions that extend into the oral, nasal or genital mucosa",{"count":63,"type":21},200,[65,66],"PHASE2","PHASE3","The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis). 5-Fluorouracil cream is currently FDA approved for the treatment of superficial basal cell carcinoma and is routinely used by dermatologists across the country and at Boston Medical Center (BMC) for SCCis. The normal treatment regimen is 4 weeks of the 5-fluorouracil cream for both skin cancers.\n\nThe application of a compounded cream consisting of 1:1 ratio 5-fluorouracil with calcipotriene will be tested. This combination cream has been shown to clear pre-skin cancers called actinic keratoses and prevent future skin cancers from developing. This combination cream for 7-14 days to see if this shorter treatment course provides clearance of the 2 types of skin cancer. This combination cream is successfully used in this manner to treat other subtypes of related skin cancers. This will be a pilot study with\n\nThe primary endpoint for this pilot randomized single blinded clinical trial will be the response to treatment (yes versus no). The lesions will be assessed clinically for clearance of cancer, as would normally be done and is consistent with how comparable studies have assessed clearance. Participants will be followed closely afterwards for three years with visits at 6 months, which does not vary from standard practice. If the lesions are not clear of cancer or equivocal clinically, the lesions will be re-biopsied and normal standard of care procedure will take place.",[27,69],"Squamous Cell Carcinoma in Situ",[71,72],"5-fluorouracil cream","fluorouracil with calcipotriene","RECRUITING","2025-11-26",{"date":76,"type":46},"2025-11-28",{"date":78,"type":46},"2022-10-15",{"date":80,"type":21},"2027-06",{"name":82,"class":53},"Boston University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":5},"100451381","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-escharex-ex-02-in-the-treatment-of-basal-cell-carcinoma-100451381","NCT05157763","A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma","An Open-Label Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma","Inclusion Criteria:\n\nInclusion Criteria- Patient level\n\n1. Male or female greater than age 18,\n2. Patients with one primary superficial or nodular basal cell carcinoma lesion (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.\n3. Lesion is present for no longer than 4 years.\n4. Lesion with a diameter of 5-10mm,\n5. Patient and\u002For legally authorized representative (LAR) understands the nature of the procedure, is able and willing to adhere to the protocol regimen, and able to provide a written informed consent prior to any study procedure.\n\nExclusion Criteria:\n\nExclusion Criteria- Patient level\n\n1. Evidence of Gorlin syndrome, neoplastic diseases (except actinic lesions), metastatic tumor or tumor with high probability of metastatic spread,\n2. Other malignant cancers (non BCC) of the skin at the lesion's site,\n3. Morphea-type basal cell carcinoma (MBCC) at the lesion's site (per biopsy report),\n4. Any signs of infection at the lesion site including purulent discharge, tissue abscess, erysipelas, cellulitis, etc.,\n5. Patients with any dermatological disease in the target lesion site or surrounding area (not including chronic actinic damage in the surrounding area),\n6. History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,\n7. Patients undergoing renal or peritoneal dialysis,\n8. Any condition that would preclude safe participation in the study, e.g. evidence of significant or unstable cardiovascular, pulmonary, liver, hematological, immunological, or any immediate life threatening condition,\n9. Concurrent acute injury or disease that might compromise the patient's welfare or the participation in the study,\n10. Current (within last 12 months) severe alcohol or drug use disorder\n11. Pregnant women (positive blood or urine pregnancy test) or nursing mothers,\n12. Exposure to investigational intervention within 4 weeks prior to enrolment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.",{"count":91,"type":21},32,[93,65],"PHASE1","This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.\n\nIn patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.",[27,28],"2021-12-01",{"date":98,"type":46},"2021-12-15",{"date":100,"type":46},"2021-06-30",{"date":102,"type":21},"2022-06",{"name":104,"class":105},"MediWound Ltd","INDUSTRY"]